• In July 2026, Halozyme Therapeutics announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, using Halozyme’s ENHANZE drug delivery technology to optimize dosing for patients with myeloproliferative neoplasms.
• This deal highlights Incyte’s push to pair its precision oncology pipeline with advanced delivery platforms, potentially broadening patient access and reinforcing its position in antibody-based therapies.
• We’ll now examine how this ENHANZE-enabled antibody delivery collaboration fits into Incyte’s investment narrative and its broader pipeline execution focus.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Incyte Investment Narrative Recap

To own Incyte, I think you need to believe the company can steadily reduce its dependence on Jakafi by converting a broad late‑stage pipeline into durable revenue, while keeping R&D and SG&A spending productive. The Halozyme ENHANZE deal around INCA033989 and the new latarcibart data both support that pipeline story, but they do not materially change the key near term catalyst, which is continued execution and label expansion across existing hematology and immunology brands, or the central risk of a future Jakafi patent cliff.

Among recent updates, the full Phase 1/2 data for latarcibart in von Willebrand disease looks especially relevant alongside the ENHANZE collaboration. Together they underscore Incyte’s push into antibody based therapies that can be given subcutaneously and potentially offer more convenient prophylaxis in chronic conditions. For the catalyst narrative, this reinforces the idea that future value may hinge on whether Incyte can turn assets like INCA033989 and latarcibart into meaningful, diversified franchises before Jakafi faces intense competition.

Yet against this opportunity, investors should still be aware of the risk that Jakafi concentration and rising pricing pressure could...

Incyte's narrative projects $6.0 billion revenue and $1.4 billion earnings by 2029.

Uncover how Incyte's forecasts yield a $108.50 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming only about US$5.9 billion of revenue and US$1.2 billion of earnings by 2029, so if you are weighing today’s ENHANZE and latarcibart news against that view, remember those forecasts reflect a much more pessimistic take on post Jakafi diversification than the baseline narrative and may shift as new data and partnerships emerge.

Explore 5 other fair value estimates on Incyte - why the stock might be worth as much as 21% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Incyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Incyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Incyte's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.